Department of Cell Biology, Duke University Medical Center, Durham, North Carolina, United States of America.
PLoS One. 2012;7(2):e32436. doi: 10.1371/journal.pone.0032436. Epub 2012 Feb 23.
Surfactant protein-A (SP-A) has well-established functions in reducing bacterial and viral infections but its role in chronic lung diseases such as asthma is unclear. Mycoplasma pneumoniae (Mp) frequently colonizes the airways of chronic asthmatics and is thought to contribute to exacerbations of asthma. Our lab has previously reported that during Mp infection of non-allergic airways, SP-A aides in maintaining airway homeostasis by inhibiting an overzealous TNF-alpha mediated response and, in allergic mice, SP-A regulates eosinophilic infiltration and inflammation of the airway. In the current study, we used an in vivo model with wild type (WT) and SP-A(-/-) allergic mice challenged with the model antigen ovalbumin (Ova) that were concurrently infected with Mp (Ova+Mp) to test the hypothesis that SP-A ameliorates Mp-induced stimulation of eosinophils. Thus, SP-A could protect allergic airways from injury due to release of eosinophil inflammatory products. SP-A deficient mice exhibit significant increases in inflammatory cells, mucus production and lung damage during concurrent allergic airway disease and infection (Ova+Mp) as compared to the WT mice of the same treatment group. In contrast, SP-A deficient mice have significantly decreased Mp burden compared to WT mice. The eosinophil specific factor, eosinophil peroxidase (EPO), which has been implicated in pathogen killing and also in epithelial dysfunction due to oxidative damage of resident lung proteins, is enhanced in samples from allergic/infected SP-A(-/-) mice as compared to WT mice. In vitro experiments using purified eosinophils and human SP-A suggest that SP-A limits the release of EPO from Mp-stimulated eosinophils thereby reducing their killing capacity. These findings are the first to demonstrate that although SP-A interferes with eosinophil-mediated biologic clearance of Mp by mediating the interaction of Mp with eosinophils, SP-A simultaneously benefits the airway by limiting inflammation and damage.
表面活性蛋白 A(SP-A)在降低细菌和病毒感染方面具有明确的功能,但它在哮喘等慢性肺部疾病中的作用尚不清楚。肺炎支原体(Mp)经常定植于慢性哮喘患者的气道中,被认为是哮喘加重的原因之一。我们的实验室之前曾报道,在非变应性气道中 Mp 感染时,SP-A 通过抑制过度的 TNF-α 介导的反应来帮助维持气道内稳态,在变应性小鼠中,SP-A 调节嗜酸性粒细胞浸润和气道炎症。在目前的研究中,我们使用了一种体内模型,该模型使用野生型(WT)和 SP-A(-/-)过敏小鼠,用模型抗原卵清蛋白(Ova)进行攻毒,同时感染 Mp(Ova+Mp),以测试 SP-A 是否能减轻 Mp 诱导的嗜酸性粒细胞刺激的假设。因此,SP-A 可以保护过敏气道免受嗜酸性粒细胞炎症产物释放引起的损伤。与同处理组的 WT 小鼠相比,SP-A 缺陷型小鼠在同时发生变应性气道疾病和感染(Ova+Mp)时,炎症细胞、黏液产生和肺损伤显著增加。相比之下,SP-A 缺陷型小鼠的 Mp 负荷明显低于 WT 小鼠。嗜酸性粒细胞特异性因子,过氧化物酶(EPO),它已被牵连在病原体杀伤,也在氧化损伤的驻留肺蛋白导致上皮功能障碍,在从变应性/感染的 SP-A(-/-)小鼠样本中增强相比 WT 小鼠。使用纯化的嗜酸性粒细胞和人 SP-A 进行的体外实验表明,SP-A 通过介导 Mp 与嗜酸性粒细胞的相互作用,限制了 EPO 从 Mp 刺激的嗜酸性粒细胞中的释放,从而降低了其杀伤能力。这些发现首次证明,尽管 SP-A 通过介导 Mp 与嗜酸性粒细胞的相互作用干扰了嗜酸性粒细胞对 Mp 的生物学清除,但 SP-A 同时通过限制炎症和损伤使气道受益。